Related Experiment Videos
Homocysteine: an emergent cardiovascular risk factor?
M A Medina1, M I Amores-Sánchez
1Universidad de Málaga, Málaga, Spain. medina@uma.es
European Journal of Clinical Investigation
|September 21, 2000
Summary
Mild hyperhomocysteinemia is increasingly recognized as a significant, independent risk factor for cardiovascular disease. This review explores homocysteine metabolism and clinical evidence supporting its role in heart disease development.
Area of Science:
- Biochemistry and Medicine
- Cardiovascular Research
Background:
- Cardiovascular disease is a primary cause of mortality and disability globally.
- Growing evidence suggests mild hyperhomocysteinemia is a key independent risk factor for cardiovascular disease.
Purpose of the Study:
- To review homocysteine's metabolic role.
- To examine the pathogenesis of hyperhomocysteinemia.
- To analyze clinical data linking hyperhomocysteinemia to cardiovascular disease risk.
Main Methods:
- Literature review of retrospective and prospective clinical studies.
- Analysis of homocysteine metabolism pathways.
- Synthesis of clinical data on hyperhomocysteinemia and cardiovascular outcomes.
Main Results:
- Homocysteine plays a crucial role in metabolic pathways.
- Hyperhomocysteinemia is linked to the pathogenesis of cardiovascular disease.
- Clinical studies consistently identify elevated homocysteine levels as an independent risk factor.
Conclusions:
- Mild hyperhomocysteinemia is a significant, independent risk factor for cardiovascular disease.
- Understanding homocysteine metabolism is vital for cardiovascular disease prevention.
- Further research into managing homocysteine levels may reduce cardiovascular disease burden.